Passage Bio Inc. and InformedDNA announced a collaboration to provide no-cost genetic counseling and testing for adults who have been diagnosed by their physicians with Frontotemporal Dementia (FTD).
Eleven months after launching with $60 million in hand, Ventus Therapeutics raised another $100 million to drive the company’s pipeline toward the clinic.
Chimeric antigen receptor (CAR-T) therapy is one of the biggest cancer therapy breakthroughs of our time, but as with any precise science, there is still some fine-tuning to be done to overcome safety risks, limited payload capacity and the prohibitive cost of manufacturing.
Researchers at Northwestern University identified a compound that appears to reverse the ongoing degeneration of upper motor neurons associated with amyotrophic lateral sclerosis (ALS).
France-based Servier and U.K.-based MiNA Therapeutics are partnering on small activating RNA (saRNA) therapies to treat neurological diseases
The U.S. Food and Drug Administration approved AstraZeneca’s top-selling treatment Tagrisso for another type of lung cancer when diagnosed at an early stage.
A roundup of biopharma news and updates includes Merck and Eisai’s Keytruda-Lenvima combo hitting the mark in a Phase III study for advanced endometrial cancer.
Five key genes are linked with the most severe form of Covid-19, scientists said, in research that also pointed to several existing drugs that could be repurposed to treat people who risk getting critically ill with the pandemic disease.
The U.S. Food and Drug Administration approved Genentech and Blueprint Medicines’ Gavreto (pralsetinib) as a treatment for adults and pediatric patients 12 and older who have been diagnosed with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC).
Intent on growing PerkinElmer’s life sciences portfolio, the company agreed to acquire cell engineering specialist Horizon Discovery Group for $383 million.